Expression of EpCAM in adenoid cystic carcinoma

Seok Joo Lee; Kee Yang Chung; Ji Eun Kwon; Sun Och Yoon; Sang Kyum Kim

doi:10.1016/j.pathol.2018.08.013

Expression of EpCAM in adenoid cystic carcinoma

Seok Joo Lee, Kee Yang Chung, Ji Eun Kwon, Sun Och Yoon, Sang Kyum Kim

Department of Pathology

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The mutational landscape of adenoid cystic carcinoma (ACC) is currently being revealed, but further studies are needed to identify biomarkers as therapeutic targets or prognostic factors of ACC. In this study, we investigated the expression of epithelial cell adhesion molecule (EpCAM) in ACCs. We retrospectively collected 83 cases of surgically resected ACCs. Using tissue microarray, we conducted immunohistochemical staining using the anti-EpCAM antibody. EpCAM expression was analysed by intensity score and the total immunostaining score. The positivity was 97.6% (81/83 cases), regardless of the intensity score. A higher histological grade (p = 0.006) and specific tumour location (non-salivary gland origin, p = 0.02) showed a correlation with higher EpCAM intensity. Higher EpCAM expression by total immunostaining score was associated with histological grade (p = 0.004), distant metastasis (p = 0.004) and poorer prognosis (overall survival p = 0.015 and progression-free survival p = 0.033). We suggest EpCAM as a candidate prognostic marker and a putative therapeutic target in ACC. Also, ACCs arising from salivary gland and non-salivary gland sites, respectively, might display different pathophysiologies in which EpCAM could play a role.

Original language	English
Pages (from-to)	737-741
Number of pages	5
Journal	Pathology
Volume	50
Issue number	7
DOIs	https://doi.org/10.1016/j.pathol.2018.08.013
Publication status	Published - 2018 Dec

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: 2016R1D1A1B03931581 ). The authors state that there are no conflicts of interest to disclose.

Publisher Copyright:
© 2018 Royal College of Pathologists of Australasia

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine

Access to Document

10.1016/j.pathol.2018.08.013

Cite this

@article{5156c8bb3d6c4ee4a9e12e6562b37f36,

title = "Expression of EpCAM in adenoid cystic carcinoma",

abstract = "The mutational landscape of adenoid cystic carcinoma (ACC) is currently being revealed, but further studies are needed to identify biomarkers as therapeutic targets or prognostic factors of ACC. In this study, we investigated the expression of epithelial cell adhesion molecule (EpCAM) in ACCs. We retrospectively collected 83 cases of surgically resected ACCs. Using tissue microarray, we conducted immunohistochemical staining using the anti-EpCAM antibody. EpCAM expression was analysed by intensity score and the total immunostaining score. The positivity was 97.6% (81/83 cases), regardless of the intensity score. A higher histological grade (p = 0.006) and specific tumour location (non-salivary gland origin, p = 0.02) showed a correlation with higher EpCAM intensity. Higher EpCAM expression by total immunostaining score was associated with histological grade (p = 0.004), distant metastasis (p = 0.004) and poorer prognosis (overall survival p = 0.015 and progression-free survival p = 0.033). We suggest EpCAM as a candidate prognostic marker and a putative therapeutic target in ACC. Also, ACCs arising from salivary gland and non-salivary gland sites, respectively, might display different pathophysiologies in which EpCAM could play a role.",

author = "Lee, {Seok Joo} and Chung, {Kee Yang} and Kwon, {Ji Eun} and Yoon, {Sun Och} and Kim, {Sang Kyum}",

note = "Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: 2016R1D1A1B03931581 ). The authors state that there are no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2018 Royal College of Pathologists of Australasia",

year = "2018",

month = dec,

doi = "10.1016/j.pathol.2018.08.013",

language = "English",

volume = "50",

pages = "737--741",

journal = "Pathology",

issn = "0031-3025",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Expression of EpCAM in adenoid cystic carcinoma

AU - Lee, Seok Joo

AU - Chung, Kee Yang

AU - Kwon, Ji Eun

AU - Yoon, Sun Och

AU - Kim, Sang Kyum

N1 - Funding Information: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: 2016R1D1A1B03931581 ). The authors state that there are no conflicts of interest to disclose. Publisher Copyright: © 2018 Royal College of Pathologists of Australasia

PY - 2018/12

Y1 - 2018/12

N2 - The mutational landscape of adenoid cystic carcinoma (ACC) is currently being revealed, but further studies are needed to identify biomarkers as therapeutic targets or prognostic factors of ACC. In this study, we investigated the expression of epithelial cell adhesion molecule (EpCAM) in ACCs. We retrospectively collected 83 cases of surgically resected ACCs. Using tissue microarray, we conducted immunohistochemical staining using the anti-EpCAM antibody. EpCAM expression was analysed by intensity score and the total immunostaining score. The positivity was 97.6% (81/83 cases), regardless of the intensity score. A higher histological grade (p = 0.006) and specific tumour location (non-salivary gland origin, p = 0.02) showed a correlation with higher EpCAM intensity. Higher EpCAM expression by total immunostaining score was associated with histological grade (p = 0.004), distant metastasis (p = 0.004) and poorer prognosis (overall survival p = 0.015 and progression-free survival p = 0.033). We suggest EpCAM as a candidate prognostic marker and a putative therapeutic target in ACC. Also, ACCs arising from salivary gland and non-salivary gland sites, respectively, might display different pathophysiologies in which EpCAM could play a role.

AB - The mutational landscape of adenoid cystic carcinoma (ACC) is currently being revealed, but further studies are needed to identify biomarkers as therapeutic targets or prognostic factors of ACC. In this study, we investigated the expression of epithelial cell adhesion molecule (EpCAM) in ACCs. We retrospectively collected 83 cases of surgically resected ACCs. Using tissue microarray, we conducted immunohistochemical staining using the anti-EpCAM antibody. EpCAM expression was analysed by intensity score and the total immunostaining score. The positivity was 97.6% (81/83 cases), regardless of the intensity score. A higher histological grade (p = 0.006) and specific tumour location (non-salivary gland origin, p = 0.02) showed a correlation with higher EpCAM intensity. Higher EpCAM expression by total immunostaining score was associated with histological grade (p = 0.004), distant metastasis (p = 0.004) and poorer prognosis (overall survival p = 0.015 and progression-free survival p = 0.033). We suggest EpCAM as a candidate prognostic marker and a putative therapeutic target in ACC. Also, ACCs arising from salivary gland and non-salivary gland sites, respectively, might display different pathophysiologies in which EpCAM could play a role.

UR - http://www.scopus.com/inward/record.url?scp=85055676421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055676421&partnerID=8YFLogxK

U2 - 10.1016/j.pathol.2018.08.013

DO - 10.1016/j.pathol.2018.08.013

M3 - Article

C2 - 30389218

AN - SCOPUS:85055676421

SN - 0031-3025

VL - 50

SP - 737

EP - 741

JO - Pathology

JF - Pathology

IS - 7

ER -

Expression of EpCAM in adenoid cystic carcinoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this